Early Detection of Cancer Saves Lives
Early Detection of Lung Cancer with Flow Cytometry
bioAffinity Technologies has developed a cost-effective, non-invasive, and accurate test called CyPath® Lung used after lung cancer screening by Low Dose CT to detect early-stage lung cancer. Physicians can order CyPath® Lung for their patients at high risk for lung cancer.
22211 W Interstate 10
San Antonio, TX 78257
Precision Pathology Laboratory Services
3300 Nacogdoches Rd Ste 110
San Antonio, TX 78217
The Harvey Sandler Cancer Research Laboratories
Science Research Laboratories
University of Texas San Antonio
San Antonio, TX 78249
Main Office: (210) 698-5334
CyPath® Lung Sales: Dallas Coleman
832-392-1655 or email@example.com
RedChip Companies, Inc.
Dave Gentry and Barrett Boone
800-RED-CHIP (800-733-2447) or 407-491-4498
bioAffinity's Diagnostics Efforts
CyPath® uses a porphyrin molecule that displays an unusually high affinity to bind to cancer cells that fluoresce brightly when labeled to distinguish cancer from non-cancer cells using flow cytometry.
Our innovative scientific research is aimed at developing non-invasive diagnostics for various cancers and other lung diseases. Our first test, CyPath® Lung, is available through Precision Pathology Laboratory Services to physicians for their patients at high risk for lung cancer.
This animated video produced by the Massachusetts Institute of Technology (MIT) Star CellBio introduces flow cytometry, a technique in which cells are suspended in a fluid and flow one at a time through a focus of exciting light, which is scattered in patterns characteristic to the cells and their components.
Cells are labeled with fluorescent markers so that light is first absorbed and then emitted at altered frequencies. A sensor detecting the emitted light measures the size and molecular characteristics of individual cells. Millions of cells can be examined in minutes and the resulting data is analyzed by computer. A picture of the lung environment is revealed by analyzing the cell populations in a sample to determine if a disease is present.
bioAffinity's Therapeutics Efforts
Through our subsidiary, OncoSelect® Therapeutics, our company focuses on advancing discoveries related to broad-spectrum cancer therapeutics. In researching porphyrins’ selectivity for cancer, we discovered novel therapies that kill cancer cells without harm to normal cells in vitro.
We will continue with animal studies to advance our discoveries. Our research also looks to attach cancer-killing cytotoxic drugs to porphyrins, a cancer-selective molecule that is taken up by tumors in much greater amounts than by non-cancer tissue.
Animation of a Porphyrin molecule